Tag: Europe
-
Grünenthal Group to Commercialize Duchenne Therapy
8 January 2015. Grünenthal Group, a German pharmaceutical company, is licensing a treatment candidate for Duchenne muscular dystrophy developed by Akashi Therapeutics, a biopharmaceutical company created by organizations advocating for research on the disease. While full financial details of the agreement were not disclosed, Grünenthal says it’s committing more than $100 million to the venture.…
-
Phillips, Banyan Partner on Point-of-Care Concussion Test
7 January 2016. A collaboration between electronics manufacturer Royal Phillips and medical diagnostics company Banyan Biomarkers Inc. is developing a handheld blood test for concussions and other mild traumatic brain injuries. Financial and intellectual property aspects of the partnership were not disclosed. Traumatic brain injury is caused by a blow or jolt to the head,…
-
Electronic Stimulation Shown to Reduce Arthritic Knee Pain
5 January 2015. Results from a clinical trial show a device emitting electronic pulses reduced more pain in the knees of people with osteoarthritis, compared to a placebo. Findings from the study, conducted by a team from University of Messina in Italy, appear in the January 2016 issue of the journal Rheumatology. The trial tested…
-
Patent Awarded for Liquid Biopsy Technology
4 January 2016. A new U.S. patent was awarded for a technology that detects a broad range of cancers in blood, rather than taking tissue samples for analysis, usually requiring surgery. Jacob Micallef, chief scientist at VolitionRx, a developer of cancer diagnostics in Namur, Belgium, received patent number 9,222,937 on 29 December 2015 from the…
-
€50,000 Challenge Seeks New Gas Technologies
28 December 2015. A challenge competition from industrial gas developer Air Liquide asks researchers to devise new solutions for three sustainable applications of gas molecules. Each of the three challenges awards a cash prize of €50,000 ($US 55,000), and an opportunity to earn another €500,000 in funding to develop the proposed solution. The competitions begin receiving entries on 6 January 2016,…
-
Biotech, Bayer Partner on Gene-Editing Treatments
21 December 2015. CRISPR Therapeutics and the drug company Bayer AG are forming a joint venture to develop gene-editing therapies for three types of genetic diseases, and later for other human and agricultural applications. The deal calls for Bayer AG, in Leverkusen, Germany, to invest at least $300 million in the joint venture and take…
-
Galapagos Licensing Inflammation Drug in $2.1B Deal
17 December 2015. A biotechnology company is licensing its small molecule drug for treating inflammatory disorders to the biopharmaceutical company Gilead Sciences in a deal valued at nearly $2.1 billion. The agreement includes Gilead Sciences taking an ownership stake in Galapagos NV, based in Mechelin, Belgium. The deal involves the small-molecule, or low molecular weight,…
-
Trial Underway Testing Opioid Dependency Treatments
15 December 2015. A late-stage clinical trial testing weekly and monthly treatments of injected buprenorphine for opioid drug dependence began enrolling patients. The trial is testing the drug code-named CAM2038 developed by the pharmaceutical company Camurus AB in Lund, Sweden, and licensed to Braeburn Pharmaceuticals in Princeton, New Jersey that offers treatments for neurological conditions.…
-
Spin-Off Developing Gene Therapies for Blood Disorders
11 December 2015. A new spin-off company from University College London in the U.K. is developing gene therapies to treat hemophilia and related diseases. The company, Freeline Therapeutics, is raising £25 million ($US 38 million) in its first venture funding round. Freeline Therapeutics is founded and commercializing research by UCL hematology professor Amit Nathwani, who…
-
University Spin-Off Develops Pain Killer Patch
8 December 2015. A new company begun by a chemistry professor in the U.K. is developing a patch infused with ibuprofen for people needing relief from pain or inflammation from arthritis. Medherant Ltd., in Coventry, is developing the patch based on research at University of Warwick conducted by David Haddleton, who founded the company and…